Hypothalamic ceramide levels regulated by CPT1C mediate the orexigenic effect of ghrelin. by Ramírez, Sara et al.
Hypothalamic Ceramide Levels Regulated by CPT1C























Recent data suggest that ghrelin exerts its orexigenic action
through regulation of hypothalamic AMP-activated protein ki-
nase pathway, leading to a decline in malonyl-CoA levels and
desinhibition of carnitine palmitoyltransferase 1A (CPT1A),
which increases mitochondrial fatty acid oxidation and ulti-
mately enhances the expression of the orexigenic neuropepti-
des agouti-related protein (AgRP) and neuropeptide Y (NPY).
However, it is unclear whether the brain-specific isoform
CPT1C, which is located in the endoplasmic reticulum of neu-
rons, may play a role in this action. Here, we demonstrate that
the orexigenic action of ghrelin is totally blunted in CPT1C
knockout (KO) mice, despite having the canonical ghrelin sig-
naling pathway activated. We also demonstrate that ghrelin
elicits a marked upregulation of hypothalamic C18:0 ceramide
levels mediated by CPT1C. Notably, central inhibition of ceram-
ide synthesis with myriocin negated the orexigenic action of
ghrelin and normalized the levels of AgRP and NPY, as well as
their key transcription factors phosphorylated cAMP-response
element–binding protein and forkhead box O1. Finally, central
treatment with ceramide induced food intake and orexigenic
neuropeptides expression in CPT1C KO mice. Overall, these
data indicate that, in addition to formerly reported mechanisms,
ghrelin also induces food intake through regulation of hypotha-
lamic CPT1C and ceramide metabolism, a finding of potential
importance for the understanding and treatment of obesity.
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G
hrelin is a hormone produced by the stomach
that induces food intake through the growth
hormone segretagogue receptor 1a in the
hypothalamus (1,2). Ghrelin and the proteins
that are involved in the downstream signaling pathway
are clear targets for the treatment of obesity and food
intake disorders. Recently, much effort has been in-
vested in studying the molecular mechanism by which
ghrelin enhances the expression of the orexigenic neuro-
peptides agouti-related protein (AgRP) and neuropeptide
Y (NPY) in the arcuate nucleus of the hypothalamus
(ARC). It has been described that ghrelin binding to
its receptor induces intracellular calcium release, which
activates hypothalamic calmodulin-dependent protein
kinase kinase 2 and the phosphorylation of the energy
sensor AMP-activated protein kinase (AMPK) (3–5). It
also has been described that ghrelin specifically trig-
gers a hypothalamic Sirtuin1/p53 pathway that is es-
sential for AMPK phosphorylation (6,7). One of the main
effects of AMPK activation in the hypothalamus is the
modulation of fatty acid metabolism; when activated,
phosphorylated AMPK (pAMPK) further phosphorylates
and inactivates acetyl-CoA carboxylase (ACC), causing
a decrease in malonyl-CoA levels and the disinhibition of
carnitine palmitoyltransferase 1 (CPT1) A enzyme (4,5).
The overall outcome of that effect is increased fatty acid
oxidation and accumulation of reactive oxygen species,
which are mainly buffered by uncoupling protein 2
(UCP2) (5). All these metabolic changes ultimately acti-
vate transcriptional events in the cell nucleus by eliciting
increased levels or activation of key transcription factors,
such as cAMP-response element–binding protein (CREB)
and its phosphorylated isoform (pCREB), forkhead box
O1 (FoxO1) and its phosphorylated isoform, and brain-
specific homeobox transcription factor. These are respon-
sible, in part, for the increase of the orexigenic neuropeptides
AgRP and NPY (8). The physiological relevance of hy-
pothalamic AMPK signaling on the orexigenic effect of
ghrelin stems from the finding that genetic or pharmaco-
logical inhibition of calmodulin-dependent protein kinase
kinase 2, AMPK, CPT1A, or UCP2, as well as increased
concentrations of malonyl-CoA levels in the hypothal-
amus block ghrelin-induced feeding (3–5). Nevertheless,
despite that compelling evidence, the exact molecular
mechanism through which changes in fatty acid metabo-
lism modulate AgRP and NPY expression is not completely
understood.
Carnitine palmitoyltransferase 1C (CPT1C) is a brain-
specific CPT1 isoform that, quite opposite to mitochondrial
CPT1A, localizes in the endoplasmic reticulum (ER) of
neurons (9). CPT1C has very low CPT1 activity but has
been demonstrated to bind malonyl-CoA (the physiological
inhibitor of CPT1 enzymes) with a Kd within the dynamic
range of hypothalamic malonyl-CoA concentration in fasted
and refed states (10,11). Consequently, CPT1C has been
proposed to be a sensor of malonyl-CoA levels in hypo-
thalamic neurons (12,13). At the physiological level, it is
well-established that hypothalamic CPT1C is involved in
the control of energy homeostasis because CPT1C knock-
out (KO) mice show reduced food intake and impaired
peripheral metabolism (11,14). However, the hypothalamic
molecular pathway through which CPT1C regulates food
intake remains unclear. We recently have demonstrated
that overexpression of CPT1C in ARC blocks the anorectic
effects of leptin through a mechanism involving increased
hypothalamic ceramide levels (15). Considering that cer-
amide levels in the mediobasal hypothalamus (MBH) are
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increased in response to fasting (15), a state in which
circulating ghrelin levels are elevated, we hypothesized
that CPT1C might be involved in the hypothalamic ghrelin
signaling pathway. Here, we demonstrate that CPT1C me-
diates a short-term increase in hypothalamic ceramide
levels in response to ghrelin and, notably, that this effect is
critical for the effects of ghrelin on AgRP and NPY ex-
pression, as well as on feeding.
RESEARCH DESIGN AND METHODS
Animal preparations. All animal procedures were performed in accordance
with the guidelines of European Community Directive 86/609/EEC (European
Union directive 86/609, European Union decree 2001–486) and Standards for
Use of Laboratory Animals A5388–01 (National Institutes of Health) and were
approved by the Local Ethics Committee. We used adult (25–30 g) CPT1C KO
male mice and their wild-type (WT) littermates. They were housed in a con-
trolled (12-h light/12-h dark) environment. The animals were fed ad libitum
with standard laboratory chow and water.
Cannulation surgery. Mice were anesthetized by an intraperitoneal (IP) in-
jection of ketamine/xylazine (ketamine 75 mg/kg body weight plus xylazine
10 mg/kg body weight). Brain infusion cannulae were stereotaxicaly placed in
the lateral cerebral ventricle using the following coordinates: 0.58 mm posterior
to bregma; 1 mm lateral to the midsagittal suture and to a depth of 2.2 mm; and
with bregma and lambda at the same vertical dimension. Former studies of our
group have demonstrated that ghrelin administration by using this route does
not affect fatty acid metabolism in other brain areas apart from MBH, such as
amygdala, striatum, habenula, fields CA1, CA2, and CA3 of the hippocampus,
hippocampus dentate gyrus, motor cortex, pyriform cortex, sensory cortex,
substantia nigra, and zona incerta (thalamus) (4). Animals were individually
caged and allowed to recover for 1 week before experiments.
Intracerebroventricular and IP treatments and sample recollection. For
the ghrelin (Bachem, Bubendorf, Switzerland) experiments, mice received an
intracerebroventricular (ICV) administration of 5 mg (dissolved in 2 mL of
physiological serum) or an IP administration of 10 mg (dissolved in 20 mL of
physiological serum) ghrelin. We have previously demonstrated that ICV
ghrelin exerts a dose-dependent effect on food intake and hypothalamic fatty
acid metabolism, with the dose of 5 mg being the one that results in a greater
response (4). The dose of 10 mg ghrelin IP has been previously used in the
literature to induce food intake and produces serum ghrelin levels in the range
observed in fasted mice (16). For the myriocin (Sigma-Aldrich, St. Louis, MO)
experiments, mice received an ICV administration of 4 mg myriocin (dissolved
in 1:3 DMSO:saline). For the C6:0 ceramide (N-hexanoyl-D-sphingosine; Sigma-
Aldrich) experiments, mice received an ICV administration of 2.5 mg C6:0
ceramide (dissolved in 1:3 DMSO:saline). Ghrelin and C6:0 ceramide were
administered at the beginning of the light cycle when mice were satiated.
When indicated, myriocin was administrated 1 h before ghrelin administration.
Mice were killed by cervical dislocation and tissue was collected. The whole
brain was used for in situ hybridization analysis, the hypothalami were used
FIG. 1. Ghrelin does not induce orexigenic effects in CPT1C KO mice. A: The 2-h food intake in WT and CPT1C KO mice treated IP with vehicle
(white bars) or with 10 mg ghrelin (black bars). B: Time to begin to eat after IP injection of vehicle (white bars) or 10 mg ghrelin (black bars).
C: The 2-h food intake in WT and CPT1C KO mice treated with ICV vehicle (white bars) or with 5 mg ICV ghrelin (black bars). ARC mRNA levels
of AgRP (D and E) and NPY (D and F) of WT and CPT1C KO mice treated with ICV vehicle (white bars) or 5 mg ghrelin (black bars). Samples were
obtained 2 h after the treatment. *P < 0.05, **P < 0.01 vs. WT mice treated with vehicle. 3V, third ventricle.
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for Western blotting, and the MBH was used for real-time PCR analysis and
ceramide measurements. To dissect the MBH, brains were placed in a coronal
brain matrix (Roboz Surgical Instrument, Gaithersburg, MD) and were sec-
tioned from bregma 21 mm to 22.5 mm. Then, a 1-mm-diameter tissue col-
lector was used to obtain the MBH from each section.
Ceramide quantification. Ceramides were extracted and analyzed via the
LC-ESI-MS/MS System (API 3000 PE Sciex; Spectralab Scientific, Markham,
Ontario, Canada) in positive ionization, as described previously (17). Their
concentrations were measured by multiple reaction monitoring experi-
ments using N-heptadecanoyl-D-erythro-sphingosine (C17 ceramide) as in-
ternal standard (50 ng$mL21). The method was linear over the range from 2
to 600 ng$mL21.
Western blotting. Hypothalamic total protein lysates (30 mg) were subjected
to SDS-PAGE, electrotransferred on a polyvinylidene fluoride membrane, and
probed with the following antibodies: phosphorylated ACC (pACC)a-Ser79
1:1,000; pAMPKa1 1:1,000; BiP 1:1,000; FoxO1 1:1,000 (Cell Signaling, Danvers,
MA); ATF-6b 1:1,000; CHOP 1:500; pCREB-Ser129 1:500; peIF2a 1:2,000;
pIKKa/b 1:1,000; IKKb 1:1,000; nuclear factor-kB 1:1,000; pPERK 1:500; TLR4
1:1,000 (Santa Cruz Biotechnology, Santa Cruz, CA); anti-b-actin 1:10,000;
ATF4 1:1,000; and 0.2 mg/mL anti-b-tubulin III (Sigma-Aldrich). Values are
expressed relative to b-actin or b-tubulin levels. The blots were developed using
the ECL Western blotting system (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK).
Real-time quantitative PCR.We performed real-time PCR (TaqMan; Applied
Biosystems, Carlsbad, CA) as described (18) using primers designed by
Applied Biosystems (AgRP Mm00475829_g1, NPY Mm00445771_m1, and
glyceraldehyde 3-phosphate dehydrogenase 4352339E) or IDT Integrated
Technologies (UCP2 63705740). Values were expressed in relation to glycer-
aldehyde 3-phosphate dehydrogenase levels.
In situ hybridization. Coronal brain sections (16 mm) were probed with
specific oligonucleotides for AgRP (59-CGA CGC GGA GAA CGA GAC TCG
CGG TTC TGT GGA TCT AGC ACC TCT GCC-39) and NPY (59-AGA TGA GAT
GTG GGG GGA AAC TAG GAA AAG TCA GGA GAG CAA GTT TCA TT-39) as
previously published (4,18–21).
Statistical analysis. We used 8–10 animals per group in all experiments
except for real-time PCR analysis, for which we used six animals. Data are
expressed as mean 6 SEM in relation (%) to vehicle-treated mice. Statistical
significance was determined by Student t test when two groups were com-
pared and by ANOVA with post hoc two-tailed Bonferroni test when more than
two groups were compared. P , 0.05 was considered significant.
RESULTS
Ghrelin administration did not increase either food
intake or the expression of orexigenic neuropeptides
in CPT1C KO mice. To establish whether CPT1C was
part of the hypothalamic ghrelin signaling pathway, we
analyzed the orexigenic effect of ghrelin in CPT1C KO
mice. We injected ghrelin IP and analyzed food intake and
FIG. 2. The ghrelin signaling pathway in WT and CPT1C KO mice. Hypothalamic protein levels of pAMPK (A and C) and pACC (B and C), MBH
mRNA levels of UCP2 measured by real-time PCR (D), and the hypothalamic protein levels of FoxO1 (E and G) and pCREB (F and G) in WT and
CPT1C KO mice after 2 h of ICV injection of vehicle (white bars) or 5 mg ICV injection of ghrelin (black bars). *P < 0.05, **P < 0.01, ***P < 0.001
vs. WT mice treated with vehicle.
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the food-seeking behavior. We found that ghrelin injection
to WT mice increased food intake two fold and highly re-
duced the time to begin eating. Both effects were com-
pletely blocked in CPT1C KO mice (Fig. 1A and B). Then,
we repeated the experiment ICV injection of ghrelin and
again found that CPT1C KO mice failed to respond to
ghrelin treatment (Fig. 1C). Next, we analyzed the ex-
pression of the orexigenic neuropeptides AgRP and NPY
by in situ hybridization. The ghrelin-induced increase in
AgRP and NPY levels present in WT mice was completely
blunted in CPT1C KO mice (Fig. 1D and E), which corre-
lates with the lack of the orexigenic effect of ghrelin in
those mice. These results indicate that CPT1C is involved
in the ghrelin orexigenic effect.
The canonical ghrelin signaling pathway is impaired
in CPT1C KO mice. Next, we analyzed the ghrelin sig-
naling pathway in hypothalamus from CPT1C KO mice.
Our data showed that central ghrelin treatment induced
a marked stimulatory effect on the levels of pAMPK,
pACC, UCP2, and the transcription factors FoxO1 and
pCREB in WT mice. Those effects were impaired in CPT1C
KO mice (Fig. 2A–G). Basal levels of pAMPK and pACC,
putative upstream factors of CPT1C, were significantly
increased in CPT1C KO mice when compared with WT
mice, suggesting that AMPK pathway is constitutively ac-
tivated in the hypothalamus of CPT1C KO mice (Fig. 2A–
C). Notably, in keeping with the altered levels of pAMPK
and pACC, the expression of UCP2, a downstream factor
of this pathway related to mitochondrial fatty acid oxida-
tion, and the levels of the transcription factors FoxO1 and
pCREB also were increased in the hypothalamus of CPT1C
KO mice when compared with vehicle-injected WT mice
(Fig. 2D–G). Therefore, these data suggest that even the
canonical signaling pathway of ghrelin is activated in
CPT1C KO mice. The lack of CPT1C blocks the ghrelin
induction of orexigenic neuropeptides and food intake.
Central administration of ghrelin increased ceramide
levels in hypothalamus of WT but not CPT1C KO
mice. Current evidence from our group has identified
CPT1C as a key regulator of ceramide levels in neurons
(22). To investigate whether ghrelin had any impact on
hypothalamic ceramide concentration, we measured the
levels of C18:0 ceramide, the most abundant ceramide in
brain and neurons (23), in WT mice at different times after
ghrelin administration. Our data showed that central
ghrelin promoted a marked stimulatory and transitory ac-
tion in C18:0 ceramide levels in the MBH, evident from the
maximal effect detected at 30 and 60 min after ghrelin
injection (Fig. 3A). Then, we performed a dose-response
curve and found that MBH ceramide levels at 30 min after
ghrelin administration increased progressively with the
dose of ghrelin, with the increase statistically significant at
the dose of 5 mg (Fig. 3B). Next, we analyzed what hap-
pened in CPT1C KO mice. Opposite to WT mice, 5 mg
ghrelin failed to induce any effect in the C18:0 ceramide
levels of CPT1C KO mice 30 min after its administration
(Fig. 3C), indicating a requirement of CPT1C for the
stimulatory effect of ghrelin on ceramide content in the
MBH.
Inhibition of hypothalamic ceramide synthesis blocked
the orexigenic effect of ghrelin. To investigate the
existence of any mechanistic link between the orexigenic
effect of ghrelin and the activation of ceramide synthesis,
we investigated the effects of 4 mg myriocin, a specific
inhibitor of the de novo synthesis of ceramide (24), on
ghrelin action. The selected dose of myriocin induced
neither an anorectic effect per se at any evaluated time
(Fig. 4A and data not shown) nor illness or malaise (data
not shown), nor hypothalamic inflammation (measured
as protein levels), nor ER stress (measured as protein
levels), an indirect indicator of inflammation (Fig. 4B
and C). Although this dose of myriocin was subeffective
when injected alone, our data showed that ICV injection
of myriocin 1 h before ghrelin administration decreased
FIG. 3. MBH ceramide levels in response to ghrelin. A: Time course of
MBH C18:0 ceramide levels in WT mice after ghrelin administration
(ICV, 5 mg). Percentage of respective increase in vehicle-treated mice is
represented. B: MBH C18:0 ceramide levels in WT after 30 min of ICV
administration of different doses of ghrelin. C: MBH C18:0 ceramide
levels of WT and CPT1C KO mice after 30 min of ICV administration of
vehicle (white bars) or 5 mg ICV administration of ghrelin (black bars).
*P < 0.05, **P < 0.01, ***P < 0.001 vs. WT vehicle. Cer, ceramide.
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FIG. 4. Myriocin injection blocks the orexigenic effect of ghrelin. WT mice were pretreated with ICV vehicle or 4 mg ICV myriocin 1 h before ICV
administration of vehicle (white bars) or 5 mg ICV administration of ghrelin (black bars). A: Food intake after 2 h of ghrelin injection. ICV injection
of myriocin does not cause ER stress (B) or inflammation (C) in hypothalamus. Hypothalamic ER stress and inflammatory markers were measured
by Western blot. ATF4, activating transcription factor 4; ATF6b, activating transcription factor 6b; BiP, ER chaperone-binding immunoglobulin
protein, also known as glucose-regulated protein 78 kDa, GRP78; CHOP-C, C/EBP homologous protein C; pEIF2a, phosphorylated eukaryotic
initiator factor 2a; pPERK, phosphorylated RNA–dependent protein kinase-like ER kinase; IKKb, IkB kinase b; pIKK ab, phosphorylated IkB
kinase ab; NFkB, nuclear factor-kB; TLR4, Toll-like receptor 4. Hypothalamic protein levels (D–F) of FoxO1 and pCREB measured by Western
blot. ARC mRNA levels (G–I) of AgRP and NPY measured by in situ hybridization. *P< 0.05, ***P< 0.001 vs. vehicle-vehicle–treated mice. 3V, third
ventricle.
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the orexigenic effect of ghrelin (Fig. 4A) and its stimu-
latory effect on transcription factors FoxO1 and pCREB
and on neuropeptides AgRP and NPY (Fig. 4D–I). These
results indicate that ceramide synthesis also is a re-
quired component of the ghrelin hypothalamic signaling
pathway.
Ceramide administration increases food intake in
CPT1C KO mice. Bearing in mind that CPT1C has been
involved in ceramide synthesis, we next investigated
whether ceramide injection had any orexigenic effect in
CPT1C KO mice; we used C6:0-ceramide, a cell-penetrating
ceramide that is converted to long chain ceramides inside
the cell (25). We used the submaximal dose of 2.5 mg,
which has been reported to block the satiating effects of
leptin but lacks of orexigenic effect per se in WT animals
(15). Of note, 2.5 mg C6:0 ceramide via ICV injection pro-
duced MBH C18:0 ceramide levels in the range observed in
ghrelin-treated mice (ICV ceramide: 0.53 6 0.10 ng C18:0
ceramide/mg protein; ICV ghrelin: 0.41 6 0.04 ng C18:0
ceramide/mg protein); in both cases, hypothalamic cer-
amide levels were significantly higher than those found in
controls (vehicle-treated). Ceramide, which was injected
at the beginning of the light cycle when animals were sa-
tiated, increased food intake and the expression of AgRP
and NPY in CPT1C KO mice but, as expected, had no effect
in WT mice (Fig. 5). These results indicate that ceramide is
able to rescue feeding patterns when the canonical ghrelin
signaling pathway (pAMPK/pACC/CPT1A/UCP2) is pre-
viously activated, as it happens in CPT1C KO mice (Fig. 2).
By contrast, in fed WT mice, which have the ghrelin ca-
nonical pathway not activated, ceramide alone is unable to
induce orexigenic neuropeptides expression and food in-
take. These results argue for two parallel signaling path-
ways for ghrelin, with the involvement of CPT1C and
ceramide in one of the branches (Fig. 6). We propose that
ghrelin must activate two parallel pathways, the mito-
chondrial pathway (with the activation of CPT1A and fatty
acid oxidation) and the ER pathway (with the activation of
CPT1C and ceramide synthesis), for its orexigenic effect to
be effective.
DISCUSSION
In this study we demonstrate that the orexigenic effect of
ghrelin is coupled to an ability of ghrelin to regulate hy-
pothalamic CPT1C and ceramide synthesis, and that this
action is required for the subsequent increase in levels of
AgRP and NPY mRNA expression in the ARC via modu-
lation of the transcription factors pCREB and FoxO1. Re-
cent data have demonstrated that the orexigenic effect of
ghrelin is mediated by the selective modulation of hy-
pothalamic SIRT1/p53/AMPK and fatty acid metabolism
pathways, as well as UCP2 levels, which culminate in in-
creased AgRP and NPY expression in the ARC (4–7). Al-
though it is clear that the modulation of hypothalamic fatty
acid metabolism is a bona fide component of ghrelin sig-
naling, it is unclear whether complex species might be
involved in that action. In fact, this is a major constraint in
our current knowledge about hypothalamic lipids and en-
ergy balance, which is restricted to a small corner of lipid
pathways, namely de novo fatty acid synthesis (regulated
by AMPK, ACC, fatty acid synthase, and malonyl-CoA
decarboxylase) and fatty acid oxidation (regulated by
CPT1A).
Current evidence from our group has implicated hypo-
thalamic ceramides and CPT1C in the actions of leptin on
food intake (15). Quite opposite to CPT1A, which is located
in the mitochondria, CPT1C resides in the ER of neurons
(9). At the cellular level, CPT1C is involved in ceramide
metabolism, which is demonstrated by the increased cer-
amide levels detected after CPT1C overexpression in vitro
and the reduced ceramide concentration detected in neu-
rons from CPT1C KO mice (22). Furthermore, our recent
data also show that genetic (adenoviral-driven) overexpres-
sion of CPT1C in the ARC increases feeding through a
mechanism involving increased ceramide levels and that
this effect antagonizes the anorectic actions of leptin at
central level (15). However, so far no evidence has linked
the orexigenic effect of ghrelin to alterations in ceramide
metabolism or hypothalamic CPT1C function. Thus, all
the evidence led us to investigate the possible involve-
ment of hypothalamic CPT1C and ceramides on the ac-
tion of ghrelin.
FIG. 5. Ceramide induces food intake in CPT1C KO mice. WT and
CPT1C KO mice were treated with ICV vehicle (white bars) or 2.5 mg
ICV ceramide C6:0 (black bars) at the beginning of the light cycle. Food
intake (A) was measured 3 h after the injection. AgRP (B) and NPY (C)
mRNA levels in MBH were measured by real-time PCR in samples
obtained 3 h after the treatment. *P < 0.05, **P < 0.01 vs. vehicle-
treated mice. CER, ceramide.
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Here, we demonstrate that central ghrelin administra-
tion promotes a marked short-term increase in the MBH
C18:0 ceramide concentration mediated by CPT1C, and
that this increase in ceramide levels is necessary to induce
hyperphagia and AgRP and NPY expression. In fact, in-
hibition of hypothalamic ceramide synthesis with myriocin
negated the orexigenic action of ghrelin treatment and
normalized AgRP and NPY expression in the ARC. Having
shown that central inhibition of ceramide synthesis
blocked the orexigenic action of ghrelin, we aimed to in-
vestigate whether ceramide treatment induced food intake
in animals fed ad libitum. Our data show that central in-
jection of ceramide increased the levels of AgRP and NPY
and induced food intake in CPT1C KO mice, which had the
ghrelin canonical pathway constitutively activated. Quite
opposite, ceramide had no effect in fed WT mice, indi-
cating that ceramide is necessary but not sufficient to in-
duce food intake. Altogether, these results indicate that,
besides the canonical SIRT1/p53/AMPK/ACC/CPT1A/UCP2
pathway, ghrelin-induced food intake is mediated by spe-
cific modulation of CPT1C and ceramide concentration in
the MBH (Fig. 6). Therefore, the reduction of hypotha-
lamic malonyl-CoA levels after ghrelin treatment (4) would
activate two parallel routes, fatty acid oxidation–mediated
by CPT1A and ceramide synthesis mediated by CPT1C,
and both routes require triggering for ghrelin to exert its
orexigenic effects. As described previously, blocking fatty
acid oxidation by inhibition of CPT1A (4) or by deletion of
FIG. 6. Schematic diagram showing the involvement of CPT1C and ceramides in the hypothalamic ghrelin signaling pathway. Ghrelin stimulates the
hypothalamic SIRT1/p53/AMPK axis, leading to decreased levels of hypothalamic malonyl-CoA, the physiological inhibitor of CPT1 enzymes. In the
“classical” mechanism of ghrelin action, this effect promotes disinhibition of CPT1A, increased fatty acid (FA) oxidation, and altered reactive
oxygen species levels. These metabolic changes ultimately activate the nuclear transcription machinery (pCREB, FoxO1, and brain-specific ho-
meobox transcription factor [BSX]), increasing mRNA expression of Agrp and Npy genes. Here, we demonstrate the existence of a parallel
downstream pathway involving CPT1C, a specific brain isoform located in the ER, which triggers a short-term increase in ceramide synthesis after
ghrelin treatment. This new pathway is of physiological importance because the orexigenic action of ghrelin is totally blunted in CPT1C KO mice or
in mice treated with an inhibitor of ceramide synthesis. The fact that central ceramide treatment induces food intake and triggers orexigenic
neuropeptides expression in CPT1C KO mice, which have the canonical ghrelin signaling pathway activated during satiating conditions, but not in
WT mice, indicates that both branches need to be activated for ghrelin to exert its orexigenic effect.
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UCP2 (5) blunts the orexigenic effects of ghrelin. The ev-
idence presented here demonstrates that the deletion of
CPT1C or the inhibition of ceramide synthesis itself also
blunts food intake after ghrelin administration, indicating
that both parallel routes are required for an appropriate
orexigenic response of ghrelin. Considering that ghrelin
and leptin are conceptualized as the "yin and yang" in the
hypothalamic regulation of feeding (26,27), our data about
ghrelin and ceramide are in agreement with those of our
previous report showing that the anorectic action of leptin
is associated with decreased ceramide concentration and
CPT1C function in the hypothalamus (15).
The cellular implications of our findings are multiple.
First, this is the first evidence linking the effect of an
orexigenic hormone, such as ghrelin, with a molecular
mechanism involving the normal function of the ER, i.e.,
ceramide synthesis. In this regard, ceramides and their
derivate sphingomyelin are one of the major lipids in plas-
matic membranes of neurons, traditionally having been
considered as structural lipids. However, current data are
challenging that view, demonstrating that ceramides can act
as signaling molecules in a bulk of processes, such as dif-
ferentiation, proliferation, apoptosis, and neuronal plastic-
ity, and can regulate the function of various kinases,
phosphatases, deacetylases, and others (28). In this sense,
ceramides could regulate the expression of orexigenic
neuropeptides AgRP and NPY by modulating the activity of
the transcription factors involved. An alternative hypothesis
might be a mechanism involving hypothalamic ER stress.
Ceramides are one of the most reactive lipid species at the
peripheral level, and impaired ceramide content in pancre-
atic b-cells and hepatocytes induces lipotoxicity and sub-
sequently ER stress (29–31). Taking into account that
hypothalamic ER stress also has been recently proposed as
a central mechanism modulating energy homeostasis and
particularly leptin resistance (32–35), it would be reason-
able to hypothesize that CPT1C, ceramide-induced lip-
otoxicity, and ER stress might play a role in the effects of
ghrelin at the hypothalamic level.
In summary, our study shows that CPT1C and ceramides
are part of a new hypothalamic mechanism mediating the
action of ghrelin on feeding through increased Agrp and
Npy gene expression. Our data also describe activation of
hypothalamic CPT1C and ceramides as mediators of food
intake, which is of potential importance for the under-
standing and treatment of obesity.
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